Propel your COVID-19 research
ACCESS THE UNDERLYING TECHNOLOGY THAT POWERS THE FIRST AND ONLY T-CELL-BASED CLINICAL TEST FOR COVID-19 TO RECEIVE EUA.
T cells are the adaptive immune system’s first responders to any virus, circulating in the blood to detect and quickly multiply to attack the virus, often before symptoms appear. Adaptive Biotechnologies’ unique MIRA Technology and immunoSEQ Technology have enabled us to create a comprehensive view of the T-cell response to SARS-CoV-2 infection. This data has been made public as part of the ImmuneCODE™ Initiative to help propel drug, vaccine, and clinical trial research.
The immunoSEQ® T-MAP™ COVID offering provides tools for researchers to study the COVID-19 T-cell immune response, including detecting past SARS-CoV-2-specific immune response in research samples & the ability to track responses longitudinally.
With immunoSEQ T-MAP COVID researchers can:
- Detect past SARS-CoV-2-specific T-cell immune response with a simple positive/negative result in research samples & track responses longitudinally.
- Search our SARS-CoV-2-specific TCR database to determine if their samples show SARS-CoV-2-specific TCRs & the antigens to which these TCR responded.
- Study the T-cell immune response for vaccine research across COVID-19 variants. Map across >160K SARS-CoV-2-specific antigen-TCR sequence-level data.
- Dive into sequence, patient or population-level data. Determine TCR clones shared between cohorts & those that are public vs private clones.
